ALB and cancer: Overall, nanomedicine has shown promising results in terms of bench-to-bedside research for cancer therapy and these innovations were responsible for early FDA approvals for Doxorubicin-loaded liposome (Doxil®) and Paclitaxel-loaded albumin nanoparticles (Abraxane®) in early 1990s.